FDA 483 - Noble Panacea Labs, Inc. - November 08, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
From November 4-8, 2024, FDA investigators Rowena S Nguyen and Rachel C Stanton inspected Noble Panacea Labs, Inc., a manufacturer located at 28 Hammond Ste E, Irvine, CA 92618-1661. The inspection identified 11 observations regarding the firm's compliance with Good Manufacturing Practices (GMP) for drug products, specifically concerning their OTC drug product, The Energist Multi-Defense Cream Broad Spectrum Sunscreen SPF 50 (1.1mL).
Key observations include:
1. **Lack of Established Written Procedures for Production and Process Controls:** * No process validation for The Energist Multi-Defense Cream Broad Spectrum Sunscreen SPF 50 (1.1mL). * Water system (NPL-EQ-[b][4]) not validated or adequately monitored; issues with testing frequency justification, unqualified personnel for microbial testing, and lack of microbial testing in qualification reports. This water was used in manufacturing two bulk lots. * Inadequate cleaning validation reports (VAL-03-00, VAL-04-00) for the [b][4] and sachet filling machines, lacking justification for product selection, demonstration of API removal (zinc oxide), and comprehensive cleaning verification tests. * Absence of procedures for using rejected finished product, testing raw materials, 100% finished product inspection, annual product
ID · 81ab6b58-7ef1-49bd-a661-07cabd76e40d
Full citation text and observation details available on the Dashboard.